Premium
Effect of a single hemodialysis session on inflammatory markers
Author(s) -
BITLA Aparna R.,
REDDY Prabhakar E.,
MANOHAR Suchitra M.,
VISHNUBHOTLA Sivakumar V.,
PEMMARAJU VENKATA LAKSHMI NARASIMHA Srinivasa Rao
Publication year - 2010
Publication title -
hemodialysis international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.658
H-Index - 47
eISSN - 1542-4758
pISSN - 1492-7535
DOI - 10.1111/j.1542-4758.2010.00491.x
Subject(s) - medicine , hemodialysis , dialysis , inflammation , lipoprotein associated phospholipase a2 , c reactive protein , end stage renal disease , gastroenterology , mann–whitney u test , cardiology , lipoprotein , cholesterol
Inflammation is a common feature of end‐stage renal disease. Although there is evidence for hemodialysis (HD)‐induced inflammatory process, the effect of a dialysis session on changes in inflammatory markers is still unclear. Seventeen patients of end‐stage renal disease on maintenance HD along with 20 age‐matched and sex‐matched healthy controls were recruited after informed consent. C‐reactive protein (CRP) and lipoprotein‐associated phospholipase A2 (LpPLA2) activity were measured in the study and control groups. Intradialytic in CRP and LpPLA2 were studied. Comparison of pre‐HD vs. the control group and predialytic and postdialytic values was performed using the Mann‐Whitney U test and Wilcoxon's test, respectively. Statistical evaluation of intradialytic changes in inflammatory markers was performed using Friedman's test. Hemodialysis patients had higher CRP levels compared with controls (P=0.001). Post‐HD LpPLA2 activity (n=17) was higher (P=0.039) compared with the pre‐HD activity. Intradialytic changes in inflammatory markers showed a significant increase (P=0.012) in LpPLA2 activity (n=7), while no change (P=0.133) was observed in CRP levels (n=17). Evidence on the pro‐inflammatory state being initiated by dialysis is provided by increased LpPLA2 activity. This may add to the atherogenic mileu and cause endothelial dysfunction in this high‐risk group. Drugs that inhibit the LpPLA2 pathway have been developed and may be effective in these patients.